percentage of annual minimum purchase requirement reduction.

No definition available.

Name:	nbrv_AnnualMinimumPurchaseRequirementPercentageReduction
Namespace Prefix:	nbrv_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of annual minimum purchase requirement reduction in year four.

+ References

No definition available.

+ Details

Name:	nbrv_AnnualMinimumPurchaseRequirementPercentageReductionInYearFour
Namespace Prefix:	nbrv_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of annual minimum purchase requirement reduction in year one to three.

+ References

No definition available.

+ Details

Name:	nbrv_AnnualMinimumPurchaseRequirementPercentageReductionInYearOneToThree
Namespace Prefix:	nbrv_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Cash payments made for amendment of agreement.

+ References

No definition available.

+ Details

Name:	nbrv_CashPaymentsForAmendmentOfAgreement
Namespace Prefix:	nbrv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of milestone payment receivable in cash upon marketing approval by the FDA with respect to any oral, intravenous or other form of fosfomycin by the company prior to acquisition.

+ References

No definition available.

+ Details

Name:	nbrv_MilestonePaymentReceivablePriorAcquisition
Namespace Prefix:	nbrv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Royalty payments to be paid.

+ References

No definition available.

+ Details

Name:	nbrv_RoyaltyPayment
Namespace Prefix:	nbrv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Threshold aggregate royalty payments that required the company to repay the difference amount at the end of royalty term.

+ References

No definition available.

+ Details

Name:	nbrv_ThresholdAggregateRoyaltyPayments
Namespace Prefix:	nbrv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of threshold milestone payment that may be settled in ordinary shares in the aggregate upon the occurrence of various specified levels of net sales with respect to the Zavante Products, prior to acquisition.

+ References

No definition available.

+ Details

Name:	nbrv_ThresholdMilestonePaymentThatMayBeSettledInOrdinaryShares
Namespace Prefix:	nbrv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- References

No definition available.

+ Details

Name:	us-gaap_BusinessCombinationsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=nbrv_ZavanteTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nbrv_HovioneSupplyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nbrv_ApprovalMilestonePaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nbrv_NetSalesMilestonePaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Details) € in Millions, $ in Millions		9 Months Ended
	Aug. 04, 2021 EUR (€)	Sep. 30, 2022	Jul. 31, 2018 USD ($)
Zavante Therapeutics
Acquisition of Zavante
Milestone payment receivable prior acquisition			$ 3.0
Threshold milestone payment that may be settled in ordinary shares			26.0
Zavante Therapeutics \| Maximum
Acquisition of Zavante
Contingent consideration			97.5
Hovione Supply Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Cash payments made for amendment of agreement \| €	€ 3.2
Threshold aggregate royalty payments \| €	4.0
Acquisition of Zavante
Percentage of annual minimum purchase requirement reduction in 2021		0.00%
Percentage of annual minimum purchase requirement reduction 2022 to 2024		50.00%
Percentage of annual minimum purchase requirement reduction in 2025		25.00%
Hovione Supply Agreement \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty payment \| €	€ 10.0
Approval Milestone Payment \| Zavante Therapeutics
Acquisition of Zavante
Contingent consideration			25.0
Net Sales Milestone Payments \| Zavante Therapeutics
Acquisition of Zavante
Contingent consideration			$ 72.5